Literature DB >> 16534635

Cytochrome P450 2D6 dependent metabolization of risperidone is inhibited by melperone.

Michael D Köhnke, Ulrich Lutz, Gerlinde Wiatr, Frank Schwärzler, Bastian Weller, Klaus Schott, Gerhard Buchkremer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16534635     DOI： 10.1007/s00228-006-0098-y

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  14 in total

1.  The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients.

Authors:  G Bondolfi; C B Eap; G Bertschy; D Zullino; A Vermeulen; P Baumann
Journal:  Pharmacopsychiatry       Date:  2002-03       Impact factor: 5.788

2.  A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A.

Authors:  J A Bork; T Rogers; P J Wedlund; J de Leon
Journal:  J Clin Psychiatry       Date:  1999-07       Impact factor: 4.384

3.  Pharmacological data of the atypical neuroleptic compound melperone (Buronil).

Authors:  E G Christensson
Journal:  Acta Psychiatr Scand Suppl       Date:  1989

4.  Venlafaxine serum levels and CYP2D6 genotype.

Authors:  A H Veefkind; P M Haffmans; E Hoencamp
Journal:  Ther Drug Monit       Date:  2000-04       Impact factor: 3.681

5.  Pharmacokinetic drug interaction potential of risperidone with cytochrome p450 isozymes as assessed by the dextromethorphan, the caffeine, and the mephenytoin test.

Authors:  C B Eap; G Bondolfi; D Zullino; C Bryois; M Fuciec; L Savary; M Jonzier-Perey; P Baumann
Journal:  Ther Drug Monit       Date:  2001-06       Impact factor: 3.681

6.  Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes.

Authors:  N Yasui-Furukori; M Hidestrand; E Spina; G Facciolá; M G Scordo; G Tybring
Journal:  Drug Metab Dispos       Date:  2001-10       Impact factor: 3.922

7.  Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans.

Authors:  E Lessard; M A Yessine; B A Hamelin; G O'Hara; J LeBlanc; J Turgeon
Journal:  Pharmacogenetics       Date:  1999-08

8.  Melperone is an inhibitor of the CYP2D6 catalyzed O-demethylation of venlafaxine.

Authors:  M Grözinger; A Dragicevic; C Hiemke; M Shams; M J Müller; S Härtter
Journal:  Pharmacopsychiatry       Date:  2003-01       Impact factor: 5.788

9.  Cytochrome P450 2D6 deficiency and its clinical relevance in a patient treated with risperidone.

Authors:  M D Köhnke; E-U Griese; D Stösser; I Gaertner; G Barth
Journal:  Pharmacopsychiatry       Date:  2002-05       Impact factor: 5.788

10.  Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat.

Authors:  L E van Beijsterveldt; R J Geerts; J E Leysen; A A Megens; H M Van den Eynde; W E Meuldermans; J J Heykants
Journal:  Psychopharmacology (Berl)       Date:  1994-02       Impact factor: 4.530
View more
  2 in total

1.  Successful treatment of schizophrenia with melperone augmentation in a patient with phenotypic CYP2D6 ultrarapid metabolization: a case report.

Authors:  Maximilian Gahr; Regina Gastl; Markus A Kölle; Carlos Schönfeldt-Lecuona; Roland W Freudenmann
Journal:  J Med Case Rep       Date:  2012-02-06

2.  Melperone but not bisoprolol or metoprolol is a clinically relevant inhibitor of CYP2D6: evidence from a therapeutic drug monitoring survey.

Authors:  Gudrun Hefner; Stefan Unterecker; Mohamed E E Shams; Margarete Wolf; Tanja Falter; Ekkehard Haen; Christoph Hiemke
Journal:  J Neural Transm (Vienna)       Date:  2015-05-05       Impact factor: 3.575
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.